• Medicine
  • Published in Cancer research 1988

Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.

@article{Harman1988PhaseIA,
  title={Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.},
  author={G S Harman and John B. Craig and John G. Kuhn and Justin S. Luther and James N. Turner and Geoffrey R. Weiss and D A Tweedy and John Koeller and Richard L. Tuttle and V. Sol Lucas},
  journal={Cancer research},
  year={1988},
  volume={48 16},
  pages={
          4706-10
        }
}
Crisnatol is a novel lipophilic arylmethylaminopropanediol with significant antineoplastic activity in a variety of murine and human tumor models which functions as a DNA intercalator. In this Phase I trial, a 6-h infusion of the drug was administered i.v. in 700 to 1500 ml of 5% dextrose in water every 28 days. Eighty-five courses at doses of 7.5 to 516 mg/m2 were administered to 43 patients with refractory solid tumors. Reversible neurological toxicity was dose limiting at 516 mg/m2 and was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-4 OF 4 CITATIONS

A phase II study of crisnatol mesylate in patients with ovarian carcinoma

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days

VIEW 5 EXCERPTS
CITES BACKGROUND

A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.

VIEW 3 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-4 OF 4 REFERENCES

Biophysical studies and murine antitumor activity of arylmethylaminopropanediols (AMAP), a new class of DNA binding drugs

  • K. W. Bair, C. W. Andrews, +3 authors M. Cory
  • Proc. Am. Assoc. Cancer Res.,
  • 1986
VIEW 1 EXCERPT

Comparative pharmacology and toxicology of three arylmethylaminopropanediols (AMAP): BWA770U; BWA773U; and BWA502U

  • B.J.M. Everitt, G. Grebe, +3 authors R. L. Tuttle
  • Proc. Am. Assoc. Cancer Res.,
  • 1986
VIEW 1 EXCERPT

Murine and human tumor stem cell activity of three candidate arylmethylaminopropanediols (AMAP)

  • V. C. Knick, R. L. Tuttle, K. W. Bair, D. D. Von Hoff
  • Proc. Am. Assoc. Cancer Res.,
  • 1986
VIEW 2 EXCERPTS

A package of computer programs for pharmacokinetic modeling

  • C. M. Metzler, G. K. Elfring, A. J. McEwer
  • Cancer Res
  • 1974
VIEW 1 EXCERPT